BRISBANE'S WORLD-FIRST ASTHMA TREATMENT

BRISBANE'S WORLD-FIRST ASTHMA TREATMENT

ASTHMA sufferers: Brisbane drug development company Invion (ASX: IVX) has partnered with a global manufacturer to progress development of a novel asthma treatment.

The inhaled INV104 has been coined as a potential new treatment for asthma, which is estimated to afflict 300 million people worldwide.

The global market for asthma therapeutics is more than $22 billion per annum.

The compound already exists but is now being reformulated for inhalation. Hovione Scienta has collaborated with Invion to develop the proprietary novel technology, which is a dry powder formulation of the compound delivered by an inhaler.

Hovione will provide expertise on chemistry, particle engineering, formulation, device and GMP manufacturing, while IVX will oversee all non-clinical and clinical development, and remain responsible for regulatory submissions.

This trajectory for growth comes as IVX has received agreement from the FDA to proceed in accelerated development of the new formulation and device.

IVX CEO and managing director Greg Collier says, both medically and commercially, the new method is superior.

"We are reformulating this compound for inhalation and remain confident that delivering this compound directly into the lung in this manner will provide superior benefit and bypass any problems associated with systemic delivery," says Collier.

"Hovione is the right partner to help us capitalise on this highly promising commercial opportunity."


Subscribe Now!
Four time-saving tips for automating your investment portfolio
Partner Content
In today's fast-paced investment landscape, time is a valuable commodity. Fortunately, w...
Etoro
Advertisement

Related Stories

Generous perks equals happy workers? Not always. Here’s what employees really want

Generous perks equals happy workers? Not always. Here’s what employees really want

Many Australian companies offer a range of benefits and perks to wo...

Fable leans in to mushrooms over ‘plant-based’, strikes deals from Wagamama UK to Zeus Street Greek

Fable leans in to mushrooms over ‘plant-based’, strikes deals from Wagamama UK to Zeus Street Greek

If there is a lesson to be learned from Fable Food Co for the ventu...

IAG slapped with class action amid claims algorithms targeted loyal customers

IAG slapped with class action amid claims algorithms targeted loyal customers

Insurance Australia Group (ASX: IAG) has been slapped with a class ...

Catalano’s ACM still keen on striking a Southern Cross deal as newspaper titles put on the table

Catalano’s ACM still keen on striking a Southern Cross deal as newspaper titles put on the table

Regional newspaper group Australian Community Media is still keen f...